LY3143921
CAS No. 1627696-53-0
LY3143921 ( LY-3143921;LY 3143921 )
Catalog No. M12416 CAS No. 1627696-53-0
LY3143921 (LY-3143921) is an orally available, potent, selective inhibitor of Cdc7 kinase inhibitor, inhibits CDC7/DBF4 I and pMCM2 (S53) with IC50 values of 3.3 nM and 290 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 88 | Get Quote |
|
10MG | 129 | Get Quote |
|
25MG | 217 | Get Quote |
|
50MG | 329 | Get Quote |
|
100MG | 503 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLY3143921
-
NoteResearch use only, not for human use.
-
Brief DescriptionLY3143921 (LY-3143921) is an orally available, potent, selective inhibitor of Cdc7 kinase inhibitor, inhibits CDC7/DBF4 I and pMCM2 (S53) with IC50 values of 3.3 nM and 290 nM, respectively.
-
DescriptionLY3143921 (LY-3143921) is an orally available, potent, selective inhibitor of Cdc7 kinase inhibitor, inhibits CDC7/DBF4 I and pMCM2 (S53) with IC50 values of 3.3 nM and 290 nM, respectively.Solid Tumors Phase 1 Clinical
-
SynonymsLY-3143921;LY 3143921
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
IndicationSolid Tumors
Chemical Information
-
CAS Number1627696-53-0
-
Formula Weight327.32
-
Molecular FormulaC16H14FN5O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1(C2=C(C=C(C=C2)C3=CNN=C3)C(=O)N1)C4=NC=NC=C4F.O
-
Chemical Name(3R)-3-(5-Fluoro-4-pyrimidinyl)-2,3-dihydro-3-methyl-6-(1H-pyrazol-4-yl)-1H-isoindol-1-one hydrate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
NG-52
NG 52 (Compound 52 ) is a potent, cell-permeable, reversible, selective, and ATP-compatible inhibitor of the cell cycle-regulating kinase.
-
NVP-2
NVP-2 is apotent, selective, ATP-competitive CDK9 inhibitor with IC50 of <0.514 nM (CDK9/CyclinT).
-
Ryuvidine
Ryuvidine is a potent, selective CDK4 inhibitor with IC50 of 6.0 uM, displays >30-fold selectivity over CDK2 (IC50>100 uM).